HomeHealth CareDrugs

Drugs

Prolacta Starts Drug Development

Howard Fine - December 11, 2023

Drugs

Arrowhead, Xencor Ink Licensing Deals Potentially Worth $1.5 Billion

Howard Fine - November 29, 2021

Drugs

USC Testing New Ultrasound Tech for Breast Cancer Screening

staff-author - September 1, 2017

Agribusiness

Pot Consultant Builds on Buzz

staff-author - January 5, 2017

Doctors

Life Sciences Get Shot In Arm in L.A.

Garrett Reim - September 29, 2016

Drugs

Pot Investors Try to Get Jump on Budding Market

Henry Meier - September 8, 2016

Drugs

Cities Mull Means to Smoke Out Tax Revenue From Recreational Weed

Howard Fine - September 8, 2016

Biotechnology

Immunotherapy Cancer Treatment Taking Flight

Hayley Fox - July 28, 2016

Drugs

FDA Approves Biosimilar, Amgen’s Rival

Joel Russell - March 6, 2015

Drugs

Health One to Stop Producing Unapproved Supplements and Drugs

Marni Usheroff - January 16, 2015

Drugs

NantWorks Strikes Deal with Sorrento Therapeutics

Marni Usheroff - December 16, 2014

Drugs

CytRx Plunges: FDA Halts Trials After Patient Death

Hannah Miet - November 18, 2014

Drugs

Report: Amgen May Bid Less for Onyx

Deborah Crowe - August 22, 2013

Drugs

FDA May Burn Smoking Business

Howard Fine - March 18, 2012

Drugs

Herbalife’s Earnings Up But Guidance Down

Joel Russell - November 1, 2011

Drugs

FDA Delays Afrezza Decision

Deborah Crowe - December 28, 2010

Drugs

Amgen Initiates Partial Drug Recall

Deborah Crowe - September 24, 2010

Drugs

Herbalife Soars on Higher Earnings, Revenue

Joel Russell - August 3, 2010

Drugs

Abraxis CEO Leaves

Deborah Crowe - January 28, 2010

Drugs

Amgen’s Profit Edges Up

Deborah Crowe - January 25, 2010

Drugs

LA Medi-Pot Ordinance Approved

staff-author - January 19, 2010

Drugs

FDA Delays Decision on MannKind Drug

Deborah Crowe - January 8, 2010

Drugs

F.D.A. Plans Safety Check of Amgen’s Anemia Drugs

staff-author - January 7, 2010

Drugs

Amgen Resolves Roche Patent Dispute

Deborah Crowe - December 22, 2009

Drugs

Prolacta Starts Drug Development

Arrowhead, Xencor Ink Licensing Deals Potentially Worth $1.5 Billion

USC Testing New Ultrasound Tech for Breast Cancer Screening

Pot Consultant Builds on Buzz

Life Sciences Get Shot In Arm in L.A.

Pot Investors Try to Get Jump on Budding Market

Cities Mull Means to Smoke Out Tax Revenue From Recreational Weed

Immunotherapy Cancer Treatment Taking Flight

FDA Approves Biosimilar, Amgen’s Rival

Health One to Stop Producing Unapproved Supplements and Drugs

NantWorks Strikes Deal with Sorrento Therapeutics

CytRx Plunges: FDA Halts Trials After Patient Death

Report: Amgen May Bid Less for Onyx

FDA May Burn Smoking Business

Herbalife’s Earnings Up But Guidance Down

FDA Delays Afrezza Decision

Amgen Initiates Partial Drug Recall

Herbalife Soars on Higher Earnings, Revenue

Abraxis CEO Leaves

Amgen’s Profit Edges Up

LA Medi-Pot Ordinance Approved

FDA Delays Decision on MannKind Drug

F.D.A. Plans Safety Check of Amgen’s Anemia Drugs

Amgen Resolves Roche Patent Dispute

Advertise with Us

About Us

Membership Center

Other Journals